阿伐替尼治疗异基因造血干细胞移植后分子生物学阳性伴KIT突变核心结合因子相关性急性髓系白血病的疗效与安全性
该研究回顾性分析河南省肿瘤医院2021年12月至2023年3月收治的6例allo-HSCT后分子生物学阳性伴KIT突变CBF-AML患者,均接受阿伐替尼治疗。治疗1个月后6例融合基因转录水平均下降,5例下降≥1 log;4例治疗≥3个月者融合基因均转阴,中位转阴时间2.0(1.0~3.0)个月。主要不良反应为骨髓抑制,多为1~2级,患者耐受性良好。
要点
- 阿伐替尼治疗1个月后6例融合基因转录水平均下降,其中5例下降≥1 log。
- 4例治疗≥3个月者融合基因均转阴,中位转阴时间2.0(1.0~3.0)个月。
- 最常见不良反应为骨髓抑制,非血液学不良反应均为1~2级。
核心结论
- 阿伐替尼可作为allo-HSCT后分子生物学阳性的伴KIT突变CBF-AML患者的有效治疗手段,主要不良反应为骨髓抑制,患者耐受性良好。
研究设计与样本
- 回顾性分析河南省肿瘤医院2021年12月至2023年3月收治的6例allo-HSCT后分子生物学阳性的伴KIT突变CBF-AML患者,均接受阿伐替尼治疗,评估疗效及安全性。
主要发现
- 阿伐替尼治疗1个月后,6例患者融合基因转录水平均较前下降,其中5例患者转录水平下降≥1 log。
- 4例患者接受阿伐替尼治疗时间≥3个月,4例患者融合基因均转阴,转阴的中位时间为2.0(1.0~3.0)个月。
- 至随访截止,4例患者无复发生存。
- 最常见的不良反应是骨髓抑制,包括中性粒细胞减少2例、血小板减少2例、贫血1例。
- 非血液学不良反应包括恶心2例、水肿1例、记忆力减退1例,均为1~2级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia (CBF-AML) with KIT mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: We retrospectively analyzed the clinical data of six patients with molecular biologically positive CBF-AML with KIT mutation after allo-HSCT, who were treated with avapritinib at Henan Cancer Hospital from December 2021 to March 2023, and evaluated the efficacy and safety of avapritinib. Results: After 1 month of treatment with avapritinib, the transcription level of the fusion gene decreased in six patients, and the transcription level decreased by ≥1 log in five patients. In four patients who received avapritinib for ≥3 months, the fusion gene turned negative, and the median time to turn negative was 2.0 (range: 1.0-3.0) months. Up to the end of follow-up, four patients had no recurrence. The most common adverse reaction of avapritinib was myelosuppression, including neutropenia in two cases, thrombocytopenia in two cases, and anemia in one case. The non-hematological adverse reactions were nausea in two cases, edema in one case, and memory loss in one case, all of which were grades 1-2. Conclusion: Avapritinib was effective for molecular biologically positive CBF-AML patients with KIT mutation after allo-HSCT. The main adverse reaction was myelosuppression, which could generally be tolerated. 目的: 探讨阿伐替尼治疗异基因造血干细胞移植(allo-HSCT)后分子生物学阳性的伴KIT突变核心结合因子相关性急性髓系白血病(CBF-AML)的疗效及安全性。 方法: 纳入河南省肿瘤医院2021年12月至2023年3月收治的6例allo-HSCT后分子生物学阳性的伴KIT突变CBF-AML患者,均接受阿伐替尼治疗,回顾性分析阿伐替尼的疗效及安全性。 结果: 阿伐替尼治疗1个月后,6例患者融合基因转录水平均较前下降,其中5例患者转录水平下降≥1 log。4例患者接受阿伐替尼治疗时间≥3个月,4例患者融合基因均转阴,转阴的中位时间为2.0(1.0~3.0)个月。至随访截止,4例患者无复发生存。最常见的不良反应是骨髓抑制,包括中性粒细胞减少2例、血小板减少2例、贫血1例。非血液学不良反应包括恶心2例、水肿1例、记忆力减退1例,均为1~2级。 结论: 阿伐替尼可作为allo-HSCT后分子生物学阳性的伴KIT突变CBF-AML患者的有效治疗手段,主要的不良反应为骨髓抑制,患者耐受性良好。.
引用
- Wang J, Zu YL, Gui RR, et al. [The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 39307723. doi:10.3760/cma.j.cn121090-20240129-00043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。